CNS Pharmaceuticals, Inc. (CNSP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, CNS Pharmaceuticals reported revenue of $0. Net income was -$15.9M, or -$35.75 per diluted share. Operating activities generated -$13.8M of cash, leaving -$13.8M of free cash flow. At fiscal year end, CNS Pharmaceuticals held $8.6M in total assets against $4.1M in total liabilities, including $7.2M of cash and equivalents.
Open the full interactive CNS Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
CNS Pharmaceuticals Key Stats
| Share Price | $5.35 |
|---|---|
| Market Cap | $36.6M |
| 52-Week Range | $2.13 – $9.54 |
| Shares Outstanding | 6.8 million (basic, 2026 Q2) |
CNS Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$9.5M | -$14.0M | -$15.3M | -$18.9M | -$14.9M | -$16.0M |
| Pre-Tax Income | -$9.5M | -$14.0M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$9.5M | -$14.0M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Diluted EPS | -$513000.00 | -$477000.00 | -$336600.00 | -$150000.00 | -$466.44 | -$35.75 |
CNS Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.2M | -$6.0M | -$4.9M | -$2.6M |
| Diluted EPS | -$5.76 | -$13.43 | -$7.30 | -$0.38 |
CNS Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.0M | $5.0M | $10.1M | $548,721 | $6.5M | $7.2M |
| Current Assets | $15.5M | $7.5M | $12.6M | $1.6M | $8.7M | $8.1M |
| Total Assets | $15.9M | $8.8M | $13.1M | $1.7M | $8.7M | $8.6M |
| Current Liabilities | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Total Liabilities | $1.9M | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Shareholders' Equity | $13.9M | $6.6M | $8.1M | -$4.4M | $6.2M | $4.5M |
CNS Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Cash From Investing | -$17,945 | -$5,748 | -$4,422 | -$3,901 | -$4,188 | -$18,175 |
| Cash From Financing | $14.1M | $4.5M | $15.6M | $4.6M | $23.0M | $14.6M |
| Free Cash Flow | -$7.3M | — | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
Figures from CNS Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CNS Pharmaceuticals financials page for every line item.
CNS Pharmaceuticals Company Profile
| Ticker | CNSP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001729427 |
Frequently Asked Questions
What was CNS Pharmaceuticals' revenue in fiscal 2025?
CNS Pharmaceuticals (CNSP) reported revenue of $0 for fiscal 2025.
What is CNS Pharmaceuticals' annual revenue history?
CNS Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was CNS Pharmaceuticals' net income in fiscal 2025?
CNS Pharmaceuticals reported net income of -$15.9M for fiscal 2025.
What was CNS Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
CNS Pharmaceuticals' diluted EPS was -$35.75 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did CNS Pharmaceuticals generate in fiscal 2025?
CNS Pharmaceuticals generated -$13.8M of free cash flow in fiscal 2025.
What was CNS Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), CNS Pharmaceuticals reported revenue of $0.
How many shares of CNS Pharmaceuticals are outstanding?
CNS Pharmaceuticals reported a weighted average of 6.8 million basic shares outstanding in 2026 Q2.
What is CNS Pharmaceuticals' market cap?
Based on its latest closing price, CNS Pharmaceuticals (CNSP) has a market capitalization of about $36.6M.
When does CNS Pharmaceuticals' fiscal year end?
CNS Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is CNS Pharmaceuticals headquartered?
CNS Pharmaceuticals lists its business address in Houston, Texas in its SEC filings.